Universitaetsklinikum Carl Gustav Carus Dresden
- Address
- 43 Blasewitzer Straße, EG, Sachsen, 01307 Dresden, Germany
Therapeutic Focus: Nervous System Diseases
The Universitätsstudienzentrum für Stoffwechselerkrankungen at Universitaetsklinikum Carl Gustav Carus Dresden concentrates its clinical research on Nervous System Diseases, aiming to advance treatments that protect and restore neurological function.
- Neuroinflammation
- Neurodegeneration
- Disease‑modifying therapies
Ongoing investigations target innovative oral agents to improve outcomes for patients with demyelinating conditions.
Disease Spotlight: Relapsing‑Remitting Multiple Sclerosis
Researchers are studying relapsing‑remitting multiple sclerosis, a common form of MS characterized by episodes of neurological deficits followed by recovery.
- MRI‑based disease activity monitoring
- Patient‑reported outcome measures
- Long‑term disability progression
The goal is to generate robust evidence that can guide clinicians in selecting effective disease‑modifying strategies.
Innovative Trial: IMU‑838 Evaluation
A double‑blind, placebo‑controlled study evaluates the impact of the oral compound IMU‑838 on disease activity in RRMS, using advanced imaging and safety assessments.
- Efficacy assessment through MRI
- Safety and tolerability profiling
- Pharmacodynamic dose‑response modeling
Findings are expected to clarify how this therapy may reduce relapse frequency and slow lesion formation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Immunic AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitaetsklinikum Carl Gustav Carus Dresden
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Vidofludimus Calcium on MRI-Assessed Disease Activity in Relapsing-Remitting Multiple Sclerosis | Immunic AG | Phase II | Recruiting | Jan 2019 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vidofludimus Calcium | 1 | Unknown | 2019-01-23 | 2019-01-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.